Tests stool transplants from new donors in adults with active ulcerative colitis
Tests fecal microbiota transplant from new donors in adults with active ulcerative colitis.
Plain-language title generated from the registry record
Registry title: Screening Donors, Fecal Microbiota Transplant Program in Ulcerative Colitis
Key facts
- Where
- Hamilton, CanadaSee the site
Where in Canada
- Hamilton Health Sciences , Mcmaster UniversityHamilton, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hamilton Health Sciences Corporation
- Trial code
- NCT04926103
- Record updated
- 1 October 2024
- Original description
The investigators intend to screen for new donors, given that there may a donor effect (PubMed ID: 25857665), with some donors not inducing remission in any patient whilst others inducing remission in 20-40% of cases. It is important to give UC patients participating in RCTs stool that has been demonstrated to be effective in some patients. We therefore propose to conduct an open label study in patients with active UC to ensure new donors are effective at inducing remission in some patients. Patients that have FMT will relapse within 18 months (PubMed ID: 25857665) although further FMT therapy induces remission so it is possible that maintenance FMT will result in long term remission, but this needs evaluation. We will therefore follow UC patients that have responded to FMT long term in this open label study.Read full original descriptionShow less
Screening Donors for a Fecal Microbiota Transplant Program in Ulcerative Colitis: Evaluating Efficacy and Long-term Effects. the FUEL Study
The investigators intend to screen for new donors, given that there may a donor effect (PubMed ID: 25857665), with some donors not inducing remission in any patient whilst others inducing remission in 20-40% of cases. It is important to give UC patients participating in RCTs stool that has been demonstrated to be effective in some patients. We therefore propose to conduct an open label study in patients with active UC to ensure new donors are effective at inducing remission in some patients. Patients that have FMT will relapse within 18 months (PubMed ID: 25857665) although further FMT therapy induces remission so it is possible that maintenance FMT will result in long term remission, but this needs evaluation. We will therefore follow UC patients that have responded to FMT long term in this open label study.
Inclusion: Patients aged 18 or over; Active UC defined as a Mayo score (7) >3; A Mayo endoscopic score (7) >0; Females of child-bearing potential must be willing and able to use acceptable contraception as per Appendix III. II. b. Toxicity section of the Health Canada Guidance.
Exclusion: Increase in medical therapy for UC in the last 12 weeks. Continued treatment with 5-ASA, azathioprine, 6-mercaptopurine or anti-TNF therapy (e.g. infliximab) will be permitted if taken at stable dose for ≥12 weeks prior to randomization. Relapse on a stable dose (same dose for at least 2 weeks) or a tapering dose of steroids will also be permitted provided the dose of steroid is not increased again. Stable intake of probiotic therapy also permitted; Antibiotic therapy in the last 30 days; Severe comorbid medical illness; Any condition, in the opinion of the investigator, that the treatment may pose a health risk to the subject; Patients with clinically significant hepatic dysfunction at the time of screening: ALT > 5 times the upper normal range; Patients with clinically significant renal dysfunction at the time of screening: serum creatinine > 300 µmol/L; Participating in another intervention study for UC; Unable to give informed consent; Severe UC requiring hospitalization; Pregnant women.